Agreements reached under this partnership
Business alliance- 1
The Company will evaluate efficacy and safety in animal studies.
- 2
トーヨーケム is expected to study the formulation of the peptides for transdermal absorption and related matters.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
FunPep is expected to bear the costs related to the activities for which it is responsible under the joint research project. However, there is no change to the forecast for research and development expenses for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | artience Co., Ltd., トーヨーケム株式会社 |
| Alliance partner's business activities | トーヨーケム is the core company of the artience Group's polymer and coating-related businesses. With the medical and healthcare fields as a priority area, it is developing transdermal formulations, adhesives, biocompatible polymers and other products. In transdermal formulations, it operates a CDMO business and conducts contract research and contract manufacturing for numerous pharmaceutical companies. |
| Type of alliance | Business alliance |
| Details of the alliance | The Company will evaluate efficacy and safety in animal studies., トーヨーケム is expected to study the formulation of the peptides for transdermal absorption and related matters. |
| Impact on Business Performance | FunPep is expected to bear the costs related to the activities for which it is responsible under the joint research project. However, there is no change to the forecast for research and development expenses for the fiscal year ending December 2026. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop transdermal formulations of antibody-inducing peptides as a next-generation formulation technology that is less invasive than injectable formulations and offers greater convenience and safety.